Back

IJOPP · Lens · Re-emerging Antibiotic- A Systematic Review on Colistin

PDF

Review · Volume 15, Issue 3 · pp. 162–166

Re-emerging Antibiotic- A Systematic Review on Colistin

Shangavi Vellingiri1, Sharmila Nirojini Palanisamy1, Nithyakala Pushpanathan1, Nithya Raju1, Malarvizhi Palanivel1, Vaishnavi Devi Chinraj1

  1. 1Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tirucehngode, Namakkal, Tamil Nadu, INDIA.

Abstract

Multidrug-resistant Gram-negative bacteria have become more common in India, and they are linked to lengthier hospital stays. Colistin (Polymyxin E) is a clinically employed antibacterial inactive prodrug of colistin sulfate and colistimethate sodium (CMS). Colistin is an antibiotic used to treat infections caused by MDR Gram-negative bacteria as a last resort. The outer membrane of gram-negative bacteria is bound by the colistin mechanism. Polymyxin E and polymyxin B are commonly utilized in practice. Recent clinical trial methods for the use of colistin with other antibiotics have shown that it can boost antibacterial efficacy, and it will be a “last-line” therapy against MDR gramnegative organisms in the twenty-first century. Clinical uses, dosing considerations, range of efficacy, toxicity level, co-administration with other antibiotics, and prospects are all revealed in the review.

Keywords: Antibiotic; Polymyxin; Colistin Methane Sulfonate; MDR- Gram-negative bacteria; Last-line therapy

The full text of this article is available as a PDF. Open the PDF.